Abstract:
We developed a high-throughput yeast-based assay to screen for chemical inhibitors of Ca2+/calmodulin-dependent kinase pathways. After screening two small libraries, we identified the novel antagonist 125-C9, a substituted ethyleneamine. In vitro kinase assays confirmed that 125-C9 inhibited several calmodulin-dependent kinases (CaMKs) competitively with Ca2+/calmodulin (Ca2+/CaM). This suggested that 125-C9 acted as an antagonist for Ca2+/CaM rather than for CaMKs. We confirmed this hypothesis by showing that 125-C9 binds directly to Ca2+/CaM using isothermal titration calorimetry. We further characterized binding of 125-C9 to Ca2+/CaM and compared its properties with those of two well-studied CaM antagonists: trifluoperazine (TFP) and W-13. Isothermal titration calorimetry revealed that binding of 125-C9 to CaM is absolutely Ca2+-dependent, likely occurs with a stoichiometry of five 125-C9 molecules to one CaM molecule, and involves an exchange of two protons at pH 7.0. Binding of 125-C9 is driven overall by entropy and appears to be competitive with T FP and W-13, which is consistent with occupation of similar binding sites. To test the effects of 125-C9 in living cells, we evaluated mitogen-stimulated re-entry of quiescent cells into proliferation and found similar, although slightly better, levels of inhibition by 125-C9 than by TFP and W-13. Our results not only define a novel Ca2+/CaM inhibitor but also reveal that chemically unique CaM antagonists can hind CaM by distinct mechanisms but similarly inhibit cellular actions of CaM.
